External validation of a heart failure risk score in patients with acute myeloid leukemia

Area of Science:

• Cardiology
• Hematology
• Oncology

Background:

• Anthracyclines are crucial for acute myeloid leukemia (AML) treatment but carry cardiotoxicity risks.
• Heart failure (HF) is a significant concern in AML patients receiving anthracycline-based chemotherapy.
• A validated risk score is needed to identify AML patients at high risk for HF.

Purpose of the Study:

• To externally validate a 21-point risk score for predicting heart failure (HF) events in acute myeloid leukemia (AML) patients.
• To assess the prognostic utility of the risk score for HF events and all-cause mortality.
• To evaluate the association between risk score categories and HF incidence and mortality.

Main Methods:

• A cohort of 193 AML patients treated with anthracycline-based therapy was analyzed.
• Patients were stratified into low, moderate, and high-risk groups using a 21-point risk score.
• Prognostic utility for HF events and all-cause mortality was assessed at one-year follow-up.

Main Results:

• Heart failure (HF) occurred in 18% of patients; incidence increased with risk score (12% low, 24% moderate, 50% high).
• A higher risk score was significantly associated with increased HF incidence (p < 0.001).
• The risk score did not demonstrate prognostic utility for all-cause mortality at one year.

Conclusions:

• The 21-point risk score is validated for predicting HF events in AML patients receiving anthracycline therapy.
• The risk score stratifies patients effectively into different HF risk categories.
• The score's utility for predicting all-cause mortality in this population requires further investigation.